Thrivent Financial for Lutherans
NBIX icon

Thrivent Financial for Lutherans’s Neurocrine Biosciences NBIX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.7M Buy
96,485
+6,167
+7% +$818K 0.02% 558
2025
Q4 		$12.8M Sell
90,318
-481,467
-84% -$69.8M 0.02% 587
2025
Q3 		$80.3M Sell
571,785
-215,514
-27% -$29.2M 0.16% 153
2025
Q2 		$99M Sell
787,299
-91,516
-10% -$10.5M 0.22% 106
2025
Q1 		$97.2M Buy
878,815
+141,043
+19% +$17.9M 0.21% 108
2024
Q4 		$101M Buy
737,772
+711,970
+2,759% +$88.1M 0.2% 124
2024
Q3 		$2.97M Sell
25,802
-20,775
-45% -$2.85M 0.01% 1189
2024
Q2 		$6.41M Buy
46,577
+21,641
+87% +$2.97M 0.01% 803
2024
Q1 		$3.44M Buy
24,936
+391
+2% +$53.4K 0.01% 1059
2023
Q4 		$3.23M Buy
24,545
+94
+0.4% +$10.8K 0.01% 1052
2023
Q3 		$2.75M Sell
24,451
-734
-3% -$77.3K 0.01% 1079
2023
Q2 		$2.38M Sell
25,185
-305
-1% -$29.8K 0.01% 1238
2023
Q1 		$2.58M Sell
25,490
-4,782
-16% -$498K 0.01% 1127
2022
Q4 		$3.62M Buy
30,272
+4,959
+20% +$581K 0.01% 917
2022
Q3 		$2.69M Buy
25,313
+238
+0.9% +$24.1K 0.01% 1052
2022
Q2 		$2.44M Buy
25,075
+285
+1% +$26.3K 0.01% 1119
2022
Q1 		$2.32M Sell
24,790
-224
-0.9% -$19K ﹤0.01% 1230
2021
Q4 		$2.13M Buy
25,014
+275
+1% +$25.3K ﹤0.01% 1356
2021
Q3 		$2.37M Sell
24,739
-360
-1% -$34K ﹤0.01% 1243
2021
Q2 		$2.44M Buy
25,099
+124
+0.5% +$11.9K 0.01% 1286
2021
Q1 		$2.43M Buy
+24,975
New +$2.62M 0.01% 1298
2020
Q4 		– Sell
-35,625
Closed -$3.42M – 2486
2020
Q3 		$3.42M Sell
35,625
-192,400
-84% -$22.3M 0.01% 914
2020
Q2 		$27.8M Buy
228,025
+1,075
+0.5% +$119K 0.08% 280
2020
Q1 		$19.6M Sell
226,950
-49
-0% -$4.79K 0.07% 318
2019
Q4 		$24.4M Buy
226,999
+20,464
+10% +$2.14M 0.07% 324
2019
Q3 		$18.6M Buy
206,535
+6,176
+3% +$577K 0.06% 342
2019
Q2 		$16.9M Buy
200,359
+14,752
+8% +$1.21M 0.05% 374
2019
Q1 		$16.4M Sell
185,607
-506,244
-73% -$42.3M 0.05% 361
2018
Q4 		$49.4M Buy
691,851
+336,101
+94% +$32.2M 0.18% 148
2018
Q3 		$43.7M Buy
355,750
+101,517
+40% +$11.5M 0.14% 181
2018
Q2 		$25M Buy
254,233
+2,834
+1% +$254K 0.08% 256
2018
Q1 		$20.8M Sell
251,399
-364
-0.1% -$30.7K 0.07% 277
2017
Q4 		$19.5M Sell
251,763
-830
-0.3% -$56.6K 0.07% 284
2017
Q3 		$15.5M Hold
252,593
– – 0.05% 313
2017
Q2 		$11.6M Hold
252,593
– – 0.05% 362
2017
Q1 		$10.9M Hold
252,593
– – 0.05% 363
2016
Q4 		$9.78M Sell
252,593
-760
-0.3% -$34.4K 0.04% 394
2016
Q3 		$12.8M Buy
253,353
+4,600
+2% +$229K 0.06% 316
2016
Q2 		$11.3M Hold
248,753
– – 0.05% 338
2016
Q1 		$9.84M Buy
248,753
+2,940
+1% +$117K 0.05% 364
2015
Q4 		$13.9M Sell
245,813
-35,530
-13% -$1.81M 0.07% 270
2015
Q3 		$11.2M Buy
281,343
+52,520
+23% +$2.54M 0.06% 310
2015
Q2 		$10.9M Buy
228,823
+4,400
+2% +$187K 0.06% 310
2015
Q1 		$8.91M Sell
224,423
-420,990
-65% -$15.1M 0.05% 362
2014
Q4 		$14.4M Sell
645,413
-10,650
-2% -$202K 0.08% 260
2014
Q3 		$10.3M Sell
656,063
-15,500
-2% -$232K 0.06% 307
2014
Q2 		$9.96M Sell
671,563
-427
-0.1% -$6.03K 0.06% 329
2014
Q1 		$10.8M Buy
671,990
+223,050
+50% +$3.82M 0.07% 287
2013
Q4 		$4.19M Buy
448,940
+109,050
+32% +$1.06M 0.03% 470
2013
Q3 		$3.85M Sell
339,890
-7,010
-2% -$96.4K 0.02% 478
2013
Q2 		$4.64K Buy
+346,900
New +$4.26M 0.03% 439

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thrivent Financial for Lutherans's NBIX Position: Q1 2026 in Review

Thrivent Financial for Lutherans increased its Neurocrine Biosciences (NBIX) stake by 6.8% in Q1 2026, buying an estimated $818K and bringing the position to 96,485 shares worth $12.7M. The position accounts for 0.02% of the portfolio, ranked #558.

Thrivent Financial for Lutherans first reported a position in NBIX in Q2 2013 and has held it in 51 quarters since. The position peaked at $101M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Thrivent Financial for Lutherans held 96,485 shares of Neurocrine Biosciences worth $12.7M as of Q1 2026.
  • Thrivent Financial for Lutherans bought 6,167 Neurocrine Biosciences shares in Q1 2026, an estimated $818K.
  • Neurocrine Biosciences made up 0.02% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #558 holding.
  • Thrivent Financial for Lutherans first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 51 quarters since.
  • Thrivent Financial for Lutherans's Neurocrine Biosciences position peaked at $101M in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.